We have examined the rate of synthesis and degradation of tyrosinase (monophenol, 3,4-dihydroxyphen-ylalanine:oxygen oxidoreductase, EC 1.14.18.1), the critical enzyme involved in mammalian pigmentation, using pulsechase metabolic labeling of murine melanoma cells and immunoprecipitation of protein extracts with antibodies directed specifically against the enzyme. We have found that tyrosinase is synthesized and glycosylated within melanocytes rapidly, since significant quantities of pulse-labeled enzyme could be detected within 30 min. Tyrosinase (monophenol, 3,4-dihydroxyphenylalanine:oxygen oxidoreductase, EC 1.14.18.1), a single-chain glycoprotein enzyme essential to pigment formation in mammals, is specifically localized in melanocytes, which occur primarily in the skin, hair bulbs, and eyes. The principal subcellular site of tyrosinase activity has been determined to be the melanosome; however, tyrosinase is demonstrable in the soluble, ribosomal, endoplasmic reticulum and Golgi apparatus fractions. Although the exact sequence of posttranslational processing is still unknown, tyrosinase appears to be synthesized on ribosomes, transferred through the endoplasmic reticulum and the Golgi apparatus, where it is glycosylated and packaged into vesicles prior to fusion with premelanosomes (1-5).
that tyrosinase activity in melanocytes is at least in part regulated by rapid synthesis and active degradation. We also have examined the melanogenic stimulation caused by melanocyte-stimulating hormone, using metabolic labeling, radiometric assays, and immunofluorescence techniques; responding cells increased their melanogenic potential more than 7-fold within 4 days without increasing their levels of tyrosinase synthesis. The results demonstrate that a pool of inactive tyrosinase exists in melanocytes and that rapid increases in enzyme activity elicited by melanocyte-stimulating hormone reflect an alteration in the activity of a preexisting pool of intracellular tyrosinase.
Tyrosinase (monophenol, 3,4-dihydroxyphenylalanine:oxygen oxidoreductase, EC 1.14.18.1), a single-chain glycoprotein enzyme essential to pigment formation in mammals, is specifically localized in melanocytes, which occur primarily in the skin, hair bulbs, and eyes. The principal subcellular site of tyrosinase activity has been determined to be the melanosome; however, tyrosinase is demonstrable in the soluble, ribosomal, endoplasmic reticulum and Golgi apparatus fractions. Although the exact sequence of posttranslational processing is still unknown, tyrosinase appears to be synthesized on ribosomes, transferred through the endoplasmic reticulum and the Golgi apparatus, where it is glycosylated and packaged into vesicles prior to fusion with premelanosomes (1) (2) (3) (4) (5) .
Tyrosinase occurs in four distinct microheterogeneous forms as identified by PAGE (6) (7) (8) ; the high molecular weight membrane-bound form of tyrosinase found in melanosomes where physiologic melanin production occurs is termed T4 tyrosinase. The other three forms (T1, T2, and T3) appear to be precursors of the T4 form of the enzyme, differing only with respect to their posttranslational modifications (9) . After solubilization of melanosomes with ionic detergents or trypsin, T4 tyrosinase is dissociated into monomeric units and shows the same electrophoretic mobility as T1 tyrosinase (10, 11), with a Mr ':70,000. Recently, some of us have succeeded in producing monoclonal antibodies specifically directed against the mature glycosylated T4 form of murine tyrosinase (12) ; these have proved to be useful in the identification and study of normal and transformed human melanocytes (13, 14) . In addition, specific antibodies against synthetic peptides encoded by the tyrosinase gene have been prepared (15) .
In this study we have examined the rate of synthesis and degradation of tyrosinase in murine melanocytes using these specific antibodies for immunoprecipitation of pulse-chase metabolically labeled cells. Further, we have used this model system to analyze the mechanisms involved in the modulation of melanogenesis in response to melanocyte-stimulating hormone (MSH), a specific differentiating stimulus that causes a dramatic increase in tyrosinase activity and pigmentation in melanocytes (16) (17) (18) (19) (20) Immunofluorescence Techniques. Cells were grown on LabTek tissue culture slides (Miles), stained for antibody localization, and photographed as described (12, 13) . Flow cytometry was performed as detailed (23) .
Melanogenic Activity Determinations. Melanogenic activities were radiometrically assayed in extracts as detailed (28, 29); briefly, the tyrosinase assay uses [3,5-3H] tyrosine (1 Ci/mmol, New England Nuclear) and measures the 3H20 released as tyrosine is hydroxylated to dihydroxyphenylalanine. The melanin formation assay uses L-[U-14C]tyrosine (100 mCi/mmol, New England Nuclear) and measures the entire melanogenic pathway; it reflects the many separate enzymatic and nonenzymatic steps required to produce melanin.
RESULTS AND DISCUSSION
MSH was shown to influence rates of melanogenesis within integumental melanocytes some time ago (30) , but it was more than a decade later before Wong and Pawelek (16) demonstrated that S91 murine melanoma cells in culture were able to respond to the hormone. Since that time, a number of studies have examined the mechanisms involved in the interaction of melanocytes with MSH, and the following sequence of events has been noted: (i) the hormone binds to melanocyte-specific surface receptors, (ii) this interaction results in a stimulation of adenylate cyclase activity and increased levels of intracellular cAMP, (iii) the elevated levels of cAMP precede increases in tyrosinase activity and melanin deposition, and (iv) there are long-term changes in the morphology and proliferation rates of the cells ( The TMH-1 antibody does not recognize the primary structure of tyrosinase but rather a specific posttranslational modification of that enzyme; its preparation and specificity has been detailed (12, 13 The earliest labeling time demonstrable for tyrosinase in this study (30 min) corresponds well with an earlier in vivo study (10) in which tritiated amino acids were used for metabolic labeling, and newly synthesized tyrosinase, detected by polyclonal antibodies, was localized in the microsomal fraction after 30 4 days of treatment with the hormone, even though increases in enzyme activity and visible pigmentation of these cells occurred (see Table 1 below). The response of melanoma cells to MSH treatment has been measured with respect to cell growth, tyrosinase activity (measured enzymatically), and tyrosinase synthesis (measured by metabolic labeling and immunoprecipitation). The changes in these parameters for B16 cells responding to MSH over a 4-day period (as they reached confluence) are shown in Fig. 4 ; there were no significant differences in the growth rates of MSH-treated and untreated cells over the course of this (or any other) short-term experiment. The tyrosinase activity in B16 cells showed only a slight increase in MSHtreated cells compared to untreated controls after 1 day, but by day 2 the enzyme activity in MSH-treated B16 cells had begun to significantly increase; this increase was maximal at day 4 and then declined toward control levels by day 8 (not shown).
In similar experiments (not shown), JB/MS cells responded even more quickly to MSH than did B16 cells; tyrosinase activity had doubled within 24 hr of MSH treatment, but again, maximal response was seen by 4 days. In contrast, the rate of enzyme synthesis by these same cells throughout the course of the experiment was virtually constitutive, with or without the addition of MSH. The tyrosinase synthesis results shown in Fig. 4 were measured by reactivity with TMH-1, but similar results were found with the anti-PEP1 Ig (Fig. 5) . We have occasionally detected increases in synthesis of tyrosinase elicited by MSH (cf. Fig.  5 at day 3 ), but these responses have never occurred before 3 days of treatment, nor has more than a 2-to 3-fold increase in synthesis ever been noted. These results are consistent with our immunofluorescence studies (Fig. 3) and indicate that melanoma cells require at least 3 days to begin responding to MSH by increasing synthesis of tyrosinase, although dramatic increases in enzyme activity precede this (see below).
To investigate whether the effects of MSH on melanoma cells might be related to changes in the rate of degradation of tyrosinase, we examined its metabolic processing in cells treated with MSH. B16 melanoma cells were incubated with MSH and, on day 4 (at maximal response) were pulse-chaselabeled and immunoprecipitated with TMH-1 and anti-PEP1 Ig as in Fig. 2 after MSH treatment compared to controls, and thus there was no change in the til2 of tyrosinase as the result of hormonally induced melanogenesis. These data agree well with other studies on S91 cells that used immunologic and enzymatic methods (34, 35) to show that MSH had no effect on the tl,2 of tyrosinase in S91 cells and, thus, that the level of action of MSH is not on enzyme stability.
In an effort to quantify the intracellular concentrations of tyrosinase in melanocytes responding to MSH, we used TMH-1 with flow cytometry. Table 1 shows a comparison of three different melanoma cell lines that respond to the hormone; B16 cells, which are slightly pigmented in culture, became highly pigmented after 4 days of MSH treatment, whereas the S91 and JB/MS amelanotic melanoma cells became only moderately pigmented under identical conditions. The melanogenic potential, determined by the melanin formation assay, reflected the visible response; B16 cells increased their rate of pigment formation about 7-fold in this experiment, while the S91 and JB/MS cell lines increased 22- (36) (37) (38) (39) that several posttyrosinase regulatory steps exist in the melanin biosynthetic pathway. Although the nature and regulatory significance of posttyrosinase factors in melanogenesis have not yet been fully elucidated, the stimulatory effects of MSH on pigmentation theoretically could result from their modulation and not from direct effects on tyrosinase activity (36, 38) . We have examined this possibility by measuring tyrosinase activity and melanin formation in MSH-treated and untreated cells; the tyrosinase assay specifically reflects that enzyme's Cell Biology: Jimenez et al. activity, whereas the melanin-formation assay reflects not only tyrosinase activity but also many other significant melanogenic factors (28, 29, 39) . Our kinetic studies on the response of B16 and JB/MS cells to MSH over a 4-day period are shown in Table 2 . Tyrosinase activity in B16 cells was stimulated approximately 6-fold after 4 days, while melanin formation was increased only 3-fold in this experiment. The ratio of the stimulations elicited by MSH of melanin formation over tyrosinase activity is shown in the far right column (M/T) of Table 2 ; a ratio of 1.0 would result if there were no effect of MSH on posttyrosinase melanin formation (that is, if MSH stimulated only tyrosinase activity), whereas the ratio might increase or decrease if MSH had an effect, depending on which factor were modulated. If blocking factor activity, for example, were reduced (suggested in ref. 36) , an increase in melanin formation relative to tyrosinase would result. In fact, in B16 cells, the M/T ratio actually decreased with time ofMSH treatment-opposite to what might be expected were posttyrosinase steps in melanin formation responsible for increased synthesis of pigment.
Similar studies on JB/MS cells are also shown in Table 2 ; after 4 days of MSH treatment, the tyrosinase activity in this experiment was stimulated 10-fold. With JB/MS cells, however, the melanin-formation assay showed a 20-fold stimulation after 4 days of MSH treatment, suggesting that modulation of posttyrosinase melanogenic factors may result in an additional 2-fold increase in melanin formation. However, the 10-fold stimulation of tyrosinase activity observed directly reflects tyrosinase activation and indicates that this is the more significant response to MSH.
Thus, it seems clear that tyrosinase is synthesized and glycosylated in melanocytes more quickly than previously thought; pulse-labeled enzyme could be detected within 30 min. The tl,2 oftyrosinase in vivo was found to be 10 hr, which suggests that melanogenesis is at least in part regulated by a relatively rapid synthesis and degradation. Further, it is clear that MSH elicits responses in melanocytes that are at least biphasic in nature-there is an increase in the rate of synthesis of tyrosinase after 4 or more days, but a more rapid stimulation of melanogenic potential occurs, which represents activation of preexisting enzyme. This rapid response to MSH results primarily from a direct effect on tyrosinase but also may partly reflect complementary effects on distal points in the melanin biosynthetic pathway. The fact that similar responses to MSH were observed on three distinct murine melanomas of diverse origin by two unique immunological probes suggests that the scheme elaborated here may reflect a general phenomenon in the response of mammalian melanocytes to this melanogenic stimulus.
